Whalesbook
Dr. Reddy's ko India ke Central Drug Standard Control Organisation (CDSCO) se officially permission mil gayi hai apni generic oral semaglutide tablets bechne ki. Yeh ek dum se badhti hui ₹1,600 Crore ki weight-loss aur diabetes ke liye jo market hai, usme entry maanne jaisa hai. Industry mein abhi kafi complexities chal rahi hain, jaise patent ke clashes, competitors ki aggressive pricing, aur doosre regions mein regulatory issues.
Approval mein 3 mg, 7 mg, aur 14 mg ke strengths wali tablets shamil hain. Clinical studies mein yeh drug Novo Nordisk ke Rybelsus se perform karne mein peeche nahi rahi. Asal mein, Dr. Reddy's ka stock 15 April 2026 ko ₹1,235.00 pe close hua tha, jisme 1.46 million shares trade hue the. Company ki market cap ₹1.03 lakh Crore hai aur P/E ratio 18.5 chal raha hai. Lekin, yeh jo patent ke lafde chal rahe hain, uski wajah se market mein thoda cautiousness ho sakti hai.
India mein GLP-1 receptor agonist market mein ek dum se change aaya hai jab Novo Nordisk ka core semaglutide patent March 2026 mein expire ho gaya. Iske baad se Sun Pharma, Zydus Lifesciences, Torrent Pharma, Lupin, aur Natco jaise doosri das se zyada domestic companies bhi apni versions launch karne ya karne ki taiyari mein hain. Torrent Pharma ne toh pehle hi SNAC concentration ko lekar ek interim agreement kar liya hai, jisme unka 0.53 mmol concentration hai, jo Novo Nordisk ke claimed range se kam hai. Dr. Reddy's ka target hai market ka lagbhag 7% hissa pakadne ka, jo Torrent ke 8% ko follow karne jaisa hai.
Novo Nordisk ke paas 2031 tak oral formulation ka patent hai, aur is patent mein SNAC concentration ek bohot hi important point hai. Yeh hi Novo Nordisk ki Dr. Reddy's aur Torrent Pharma ke khilaaf chal rahi litigation ka focus hai. Novo Nordisk ka kehna hai ki unka specific SNAC formulation 0.65-2.1 mmol range mein aata hai. Yeh legal uncertainty Dr. Reddy's ke market access ko restrict kar sakti hai ya phir costly settlements ho sakte hain.
Pure weight-loss drug sector mein bohot growth dikhi hai, jisme Rybelsus kaafi bada share rakhta hai. Lekin ab jab generics ki flood aane wali hai, toh prices mein 50-85% tak ki kami aane ki prediction hai, jisse sabhi players ke profit margins par pressure padega.
Aur problems ki baat karein toh, Dr. Reddy's ko Brazil mein bhi ek regulatory setback mila hai. Wahan ki ANVISA ne inki semaglutide generic, Embeltah, ki registration deny kar di hai, jiske reasons efficacy, safety aur quality mein issues bataye gaye hain. Is rejection se Brazil jaise important market mein entry karne ke chances kam ho gaye hain.
Abhi bhi kuch analysts positive hain. HSBC ne Dr. Reddy's ko 'Buy' rating di hai aur target price ₹1,445 rakha hai, jiska reason semaglutide ka long-term potential aur FY27-28 ke liye improved earnings estimates hai. Woh company ke core business aur biosimilar platform ko bhi stable maan rahe hain. Doosri taraf, Citi abhi bhi cautious hai aur valuation issues aur badhti competition ko risk maan raha hai. Citi ka target price ₹1,070 hai. Aage market kaisa chalega, yeh SNAC patent disputes ke resolution aur competition ke beech Dr. Reddy's kaise strategy execute karti hai, us par depend karega.